Atria Investments Inc Has $1.34 Million Holdings in Neurocrine Biosciences, Inc. $NBIX

Atria Investments Inc lifted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 15.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 10,674 shares of the company’s stock after purchasing an additional 1,415 shares during the period. Atria Investments Inc’s holdings in Neurocrine Biosciences were worth $1,342,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of NBIX. Y Intercept Hong Kong Ltd bought a new stake in Neurocrine Biosciences in the first quarter valued at approximately $1,460,000. Assetmark Inc. increased its stake in Neurocrine Biosciences by 10.8% in the second quarter. Assetmark Inc. now owns 21,001 shares of the company’s stock valued at $2,640,000 after purchasing an additional 2,045 shares in the last quarter. Financiere des Professionnels Fonds d investissement inc. bought a new stake in Neurocrine Biosciences in the second quarter valued at approximately $696,000. Wealth Enhancement Advisory Services LLC increased its stake in Neurocrine Biosciences by 229.1% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 19,107 shares of the company’s stock valued at $2,467,000 after purchasing an additional 13,301 shares in the last quarter. Finally, Envestnet Asset Management Inc. increased its stake in Neurocrine Biosciences by 61.9% in the second quarter. Envestnet Asset Management Inc. now owns 198,039 shares of the company’s stock valued at $24,891,000 after purchasing an additional 75,733 shares in the last quarter. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CEO Kyle Gano sold 300 shares of the firm’s stock in a transaction dated Tuesday, November 4th. The shares were sold at an average price of $141.97, for a total transaction of $42,591.00. Following the transaction, the chief executive officer directly owned 140,407 shares of the company’s stock, valued at approximately $19,933,581.79. This trade represents a 0.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 4.30% of the company’s stock.

Analyst Upgrades and Downgrades

NBIX has been the subject of several recent analyst reports. UBS Group upped their target price on shares of Neurocrine Biosciences from $188.00 to $195.00 and gave the company a “buy” rating in a research note on Thursday, October 9th. Stifel Nicolaus upped their price target on shares of Neurocrine Biosciences from $174.00 to $183.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Wedbush reiterated an “outperform” rating on shares of Neurocrine Biosciences in a report on Monday, September 22nd. Morgan Stanley upped their price target on shares of Neurocrine Biosciences from $163.00 to $168.00 and gave the company an “overweight” rating in a report on Monday, October 20th. Finally, Piper Sandler upped their price target on shares of Neurocrine Biosciences from $175.00 to $179.00 and gave the company an “overweight” rating in a report on Wednesday, October 29th. One analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $170.26.

Neurocrine Biosciences Stock Performance

NASDAQ NBIX opened at $153.75 on Thursday. The firm has a 50-day moving average of $141.45 and a 200-day moving average of $130.70. The stock has a market cap of $15.33 billion, a PE ratio of 36.78, a P/E/G ratio of 0.94 and a beta of 0.22. Neurocrine Biosciences, Inc. has a 52-week low of $84.23 and a 52-week high of $157.67.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Tuesday, October 28th. The company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.58 by $0.46. The company had revenue of $794.90 million during the quarter, compared to analysts’ expectations of $746.61 million. Neurocrine Biosciences had a net margin of 15.95% and a return on equity of 15.82%. Neurocrine Biosciences’s quarterly revenue was up 27.8% compared to the same quarter last year. During the same quarter last year, the company posted $1.81 EPS. As a group, analysts predict that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current fiscal year.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.